Director Shareholding

RNS Number : 6221Z

Alliance Pharma PLC

08 March 2013

 



For immediate release

8 March 2013

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the admission of 476,190 ordinary shares of 1 pence each in the Company ("Ordinary Shares") on 8 March 2013 following the conversion of some of the Company's Convertible Unsecured Loan Stock, which increased the Company's issued share capital to 244,963,702 Ordinary Shares, the direct shareholding of John Dawson, Chief Executive, of 24,460,079 Ordinary Shares, has been diluted to 9.99% of the issued share capital of the Company.

Mr Dawson's total beneficial holding of 40,036,402 Ordinary Shares represents 16.34% of the issued share capital of the Company, and his total beneficial and non-beneficial holding of 60,036,402 Ordinary Shares represents 24.51% of the Company's issued share capital.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

MSCJPMITMBIMBPJ